Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 21,493,300 | 19,973,800 | 21,222,100 | 19,958,700 | 19,615,600 |
| Cost of Goods | 4,681,700 | 4,447,700 | 5,710,100 | 5,037,200 | 4,932,500 |
| Gross Profit | 16,811,600 | 15,526,100 | 15,512,000 | 14,921,500 | 14,683,100 |
| Operating Expenses | 13,277,800 | 13,523,500 | 12,250,900 | 12,232,300 | 12,023,800 |
| Operating Income | 3,534,500 | 2,003,301 | 3,261,199 | 2,689,400 | 2,659,801 |
| Other Income | 145,600 | 301,499 | 112,801 | 100,600 | 340,499 |
| Pre-tax Income | 3,680,100 | 2,304,800 | 3,374,000 | 2,790,000 | 3,000,300 |
| Income Tax | 529,500 | 2,391,200 | 636,400 | 381,600 | 609,800 |
| Net Income Continuous | 3,150,600 | -86,400 | 2,737,600 | 2,408,400 | 2,390,500 |
| Net Income Discontinuous | 81,400 | -117,700 | N/A | N/A | N/A |
| Net Income | $3,232,000 | $-204,100 | $2,737,600 | $2,408,400 | $2,390,500 |
| EPS Basic Total Ops | 3.14 | -0.19 | 2.59 | 2.27 | 2.23 |
| EPS Basic Continuous Ops | 3.07 | -0.08 | 2.59 | 2.27 | 2.23 |
| EPS Basic Discontinuous Ops | 0.07 | -0.11 | N/A | N/A | N/A |
| EPS Diluted Total Ops | 3.13 | -0.19 | 2.58 | 2.26 | 2.23 |
| EPS Diluted Continuous Ops | 3.05 | -0.08 | 2.58 | 2.26 | 2.23 |
| EPS Diluted Discontinuous Ops | 0.08 | -0.11 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | 5.55 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $5,143,500 | $3,570,601 | $4,757,799 | $4,117,101 | $4,038,801 |